Mathematical model measures stress level needed to produce cell death. Model could eventually be applied in other cancers. PHILADELPHIA — Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the...
Posted to
News
by
AACR News
on
Thu, Jan 17 2013
Filed under:
Filed under: Press Releases, Research, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, Cancer Research, colorectal cancer, journal, predict, model, DR_MOMP, MOMP, Dr. Jochen J.M. Prehn, mitochondrial outer membrane permeabilization, BCL-2
“Chemo brain” may be an inaccurate descriptor of cognitive issues. Fatigue is a key contributor to cognitive problems. Interventions to reduce stress and fatigue may alleviate postchemotherapy neurocognitive problems. SAN ANTONIO — Women undergoing chemotherapy who experience cognitive...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, women, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, fatigue, Dr. Bernadine Cimprich, chemo brain
Safety profile was consistent with previous trials of bevacizumab. More understanding of triple-negative breast cancer is still needed. Final overall survival data are expected in 2013. SAN ANTONIO — Patients who received one year of bevacizumab in addition to chemotherapy for the postsurgical...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, triple-negative breast cancer, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, bevacizumab, Dr. David Cameron, BEATRICE study
Breast tumor aggressiveness increased receipt of chemotherapy, decreased adjuvant radiation utilization. Adjuvant radiation still under-recommended. Receiving chemotherapy decreased likelihood of radiation. SAN DIEGO — Women with aggressive breast cancer were more likely to receive adjuvant chemotherapy...
Posted to
News
by
AACR News
on
Sun, Oct 28 2012
Filed under:
Filed under: Press Releases, Research, Breast Cancer, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, minorities, women, Disparities, cancer health disparities, The Science of Cancer Health Disparities, Radiation therapy, Susan G. Komen Cancer Disparities Research, Abigail Silva
Disease has high heterogeneity. First-line chemosensitivity associated with subsequent chemoresistance. Gene identified that may predict chemoresistance. PHILADELPHIA — The presence of multiple ovarian cancer genomes in an individual patient and the absence or downregulation of the gene LRP1B are...
Posted to
News
by
AACR News
on
Wed, Aug 15 2012
Filed under:
Filed under: Press Releases, Research, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, Cancer Research, women, ovarian cancer, journal, gene, chemoresistance, LRP1B, Dr. David Bowtell
BAY 86-9766 offers survival benefit in mouse model of pancreatic cancer. Treatment yields remarkable tumor regression rapidly. Therapy effective in mice with advanced tumors. LAKE TAHOE, Nev. — A novel chemotherapeutic agent, the highly selective MEK1/2 inhibitor BAY 86-9766, may be a promising...
Posted to
News
by
AACR News
on
Wed, Jun 20 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, pancreatic cancer, preclinical studies, Pancreatic Cancer: Progress and Challenges, Dr. Nicole Teichmann
Lower doses of IL-2 and 13-cis retinoic acid increased natural “killer” cells. Combination therapy might benefit patients with stage 4 cancers. Patients who received this combination had improved survival rates. CHICAGO — Maintenance therapy with interleukin-2 and 13-cis retinoic acid...
Posted to
News
by
AACR News
on
Mon, Apr 2 2012
Filed under:
Filed under: Press Releases, Research, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, meeting, 2012 Annual Meeting, Annual Meeting, immunotherapy, AACR Annual Meeting 2012, interleukin-2, Dr. Francesco Recchia, stage 4 cancer, 13-cis retinoic acid, IL-2, maintenance therapy
Assay could direct treatment options for triple-negative breast cancer. Accumulations of telomere AI predicted sensitivity to therapy. PHILADELPHIA — Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin...
Posted to
News
by
AACR News
on
Thu, Mar 22 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, chemotherapy, women, journal, triple-negative breast cancer, tAI, telomeric allelic imbalance, platinum chemotherapy, cisplatin, carboplatin, Dr. Andrea Richardson
Tweet • Flu vaccine could be used to test immune response. • Patients presented with metastatic renal cell cancer. • Implications beyond quality of life and patient management. PHILADELPHIA — Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents...
Posted to
News
by
AACR News
on
Tue, Jun 28 2011
Filed under:
Filed under: Press Releases, Research, influenza, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, Radboud University Nijmegen Medical Center, sorafenib, Keith Flaherty, flu vaccine, immune system, metastatic renal cell cancer, Clinical Cancer Research, sunitinib, The Netherlands, Carla van Herpen